samedan logo
 
 
spacer
home > epc > spring 2007 > antibiotics under attack
PUBLICATIONS
European Pharmaceutical Contractor

Antibiotics Under Attack

Sylvia Miriyam Findlay of Frost & Sullivan examines the threat posed to the anti-infective industry by multi-resistant bacteria

The advent of antibiotics was a boon for many suffering from serious infections. Lately, however, the indiscriminate use of antibiotics has led to severe public health issues. Harmful micro-organisms are becoming resistant to antibiotics currently in use, and this situation is likely to endanger the future of antibiotic treatment if urgent action is not taken.

THE ISSUE

Antibiotic abuse has contributed to spiralling public healthcare expenditure and governments are realising the importance of curbing the indiscriminate use of these drugs. Physicians find it increasingly difficult to treat infections and patients are forced to stay longer in hospitals, since resistant strains consume more antibiotics, creating longer treatment regimens. This situation is exerting immense pressure on governments to loosen their purse strings and increase public health spending.

The lack of knowledge surrounding the etiology of various infections is another factor in the increasing use of antibiotics. Prescription of these drugs lies solely at the discretion of physicians and, in the absence of unambiguous diagnostic tests and robust guidelines regulating their use, the issue is becoming critical.

The use of antibiotics varies across Europe. Northern regions have low usage rates, while the eastern and southern regions have moderate and high usage respectively. The use of broad spectrum antibiotics has increased over the years, confirming the fact that an increased use of antibiotics leads to multi-resistant bacteria. It has been estimated that the US spends $5 billion annually on this cause. If left unaddressed, this scenario is likely to have a serious economic impact in years to come. Tough bacteria that have outwitted the first and second generation antibiotics are now traversing to the higher generation drugs. Normal medical procedures and various medical interventions are likely to become ineffective if we remain unarmed against such a treacherous invasion.


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Sylvia Miriyam Findlay is a Research Analyst with the pharmaceutical-biotechnology team for the EMEA healthcare practice of Frost & Sullivan. She has over five years of experience as an Executive Territory Manager in Eli Lilly & Co India. Sylvia has authored research projects on the European diabetes market and the impact of the emerging non-invasive delivery systems and is currently analysing the European respiratory diseases market. Sylvia holds a Bachelors degree in Zoology with Biotechnology from the Women’s Christian College and a first class Masters degree in Life Sciences from Pondicherry University. She has presented various scientific papers during her academic years.
spacer
Sylvia Miriyam Findlay
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

Small Scale Biomanufacturing – clinical trials, cell & gene therapies

18 September 2008, Clifton Pavilion, Bristol Zoo Gardens, Bristol

This one day conference, sponsored by bioProcessUK and organised by BioApproaches South West, will cover key, important topics relating to small scale GMP biomanufacturing.
More info >>

 
News and Press Releases

“PACK DIFFERENT” with EMBALLAGE 2008

“Business, Innovation, Outlook” are the watchwords for the 38th World Packaging Exhibition which opens in Paris from 17 to 21 November 2008. Fifteen months before the key packaging event of the end of 2008, EMBALLAGE displays its differences to offer you a new edition that is even more representative, international and rich in new features.
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement